Glycemic status and risk of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 628-635

  Darbinian, Jeanne A ^a   Ferrara, Assiamira M ^a   Van Den Eeden, Stephen K ^a   Quesenberry Jr , Charles P ^a   Fireman, Bruce ^a   Habel, Laurel A ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CALIFORNIA; COHORT STUDIES; DIABETES MELLITUS; GLYCEMIC INDEX; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK;

EID: 41549103209     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2610     Document Type: Article

References (62)

1. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001;23:3-13.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
3. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990;50:169-73.
4. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
5. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847-53.
6. Hsing AW, Gao YT, Chua S, Jr., Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003;95:67-71.
7. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002;3:303-8.
8. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev 2001;23:42-58.
9. Pollak M. Insulin-like growth factors and prostate cancer. Epidemiol Rev 2001;23:59-66.
10. Saad MF, Knowler WC, Pettitt DJ, et al. A two-step model for development of non-insulin-dependent diabetes. Am J Med 1991;90:229-35.
11. Giovannucci E. Medical history and etiology of prostate cancer. Epidemiol Rev 2001;23:159-62.
12. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992;117:807-11.
13. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990;132:895-901.
14. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002;25:55-60.
15. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L; MRFIT Research Group. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;143:889-97.
16. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-41.
17. Thompson MM, Garland C, Barrett-Connor E, et al. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol 1989;129:511-7.
18. Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992;136:1110-4.
19. Batty GD, Shipley MJ, Marmot M, Smith GD. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control 2004;15:873-81.
20. Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev 1995;4:807-11.
21. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-5.
22. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998;9:3-9.
23. Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999;10:313-8.
24. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002;102:258-61.
25. Rodriguez C, Patel AV, Mondul AM, et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005;161:147-52.
26. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202.
27. Tavani A, Gallus S, Bosetti C, et al. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002;11:125-8.
28. Tavani A, Gallus S, Bertuzzi M, et al. Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 2005;47:313-7.
29. Rosenberg DJ, Neugut AI, Ahsan H, Shea S. Diabetes mellitus and the risk of prostate cancer. Cancer Invest 2002;20:157-65.
30. Coker AL, Sanderson M, Zheng W, Fadden MK. Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer 2004;90:2171-5.
31. Zhu K, Lee IM, Sesso HD, et al. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004;159:978-82.
32. Gonzalez-Perez A, Garcia Rodriguez LA. Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 2005;16:1055-8.
33. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006;15:1977-83.
34. Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006;166:1871-7.
35. Lightfoot N, Conlon M, Kreiger N, et al. Medical history, sexual, and maturational factors and prostate cancer risk. Ann Epidemiol 2004;14:655-62.
36. Calton BA, Chang SC, Wright ME, et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007;18:493-503.
37. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-Year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol 1990;131:254-62.
38. Gapstur SM, Gann PH, Colangelo LA, et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 2001;12:763-72.
39. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2056-62.
40. Collen MF. History of MHTS. In: Collen MF, editor. Multiphasic health testing services. New York: John Wiley and Sons; 1978. p. 1-45.
41. Friedman GD. Effects of MHTS on patients. In: Collen MF, editor. Multiphasic health testing services. New York: John Wiley and Sons; 1978. p. 531-49.
42. Lowe LP, Liu K, Greenland P, et al. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163-9.
43. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Tech Rep Ser 2000;894:i-253.
44. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002;87:4522-7.
45. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003;35:694-704.
46. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of noninsulin-dependent diabetes. In: National Diabetes Data Group, editor. Diabetes in America. 2nd ed. Bethesda: NIH, National Institute of Diabetes and Digestive and Kidney Diseases; NIH Publ 95-1468; 1995. p. 47-67.
47. Fontana SA, Baumann LC, Helberg C, Love RR. The delivery of preventive services in primary care practices according to chronic disease status. Am J Public Health 1997;87:1190-6.
48. Enger SM, Van Den Eeden SK, Sternfeld B, et al. California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health 2006;6:172.
49. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. JAMA 2002;287:2519-27.
50. Djavan B, Bursa B, Seitz C, et al. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology 1999;54:603-6.
51. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
52. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000;36:1224-8.
53. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
54. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
55. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
56. Stattin P, Rinaldi S, Biessy C, et al. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12.
57. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-65.
58. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001;85:991-6.
59. Haffner SM, Karhapaa P, Mykkanen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 1994;43:212-9.
60. Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000;23:912-8.
61. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999;80:930-4.
62. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418-24.